A Randomized, Open Label, Multicenter, Phase 2/3 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia.
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Lumiliximab (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms LUCID
- Sponsors Biogen
- 05 Oct 2021 This trial has been completed in Spain and France according to European Clinical Trials Database record. (End date: 2010-04-07)
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 07 Feb 2011 Trial phase changed from II to II/III as reported by Clinical Trials Registry - India.